About this site

What CJC-1295 Dr. is

CJC-1295 Dr. is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 — a synthetic GHRH analog developed by ConjuChem Biotechnologies and studied in Phase 1/2 human trials published in 2006. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'Dr.' in the domain name is editorial framing — the position of a careful reader of the literature, not a claim of clinical credentials or professional health services. This site does not employ physicians, does not provide consultations, does not offer diagnoses or treatment recommendations, and has no affiliation with any healthcare provider or pharmaceutical vendor. Reading this site is not a substitute for consultation with a qualified healthcare professional.

Editorial standards

Every quantitative claim on this site — a dose value, a half-life number, a percentage change, a study outcome — is cited to a peer-reviewed publication. The primary sources are:

• PubMed and PubMed Central (NIH) for indexed peer-reviewed journals
• The original journal publications (accessed via DOI)
• ClinicalTrials.gov for registered trial records where applicable
• WADA prohibited list for anti-doping classification
• FDA regulatory databases for classification and compounding status

Secondary sources, forum posts, and commercial vendor claims are not cited and do not influence the content. Where the published literature is silent, this site says so. Where the evidence base has gaps — as it does for CJC-1295, which has no Phase 3 data and no long-term safety dataset — the gaps are identified explicitly.

This site distinguishes between direct CJC-1295 data (Phase 1 human trials, rodent mechanistic studies) and class-level inferences from related GHRH analog compounds (Schally laboratory's MR-409, MR-502). Extrapolating across GHRH analogs requires caution; this site notes when a finding is class-level rather than compound-specific.

What CJC-1295 Dr. is not

CJC-1295 Dr. is not a medical practice, pharmacy, telehealth service, or vendor of any kind. It does not recommend doses, treatment regimens, or products. It does not have a clinical team. It does not sell or distribute CJC-1295 or any other compound. It is not affiliated with ConjuChem Biotechnologies, WADA, the FDA, or any laboratory, vendor, or healthcare organization.

The site name and domain use the word 'Dr.' to position the publication as a careful, informed reader of the literature — not as a licensed clinical entity. We are explicit about this distinction to avoid any ambiguity about the nature of the service: this is an editorial publication, governed by editorial standards, not a healthcare service governed by clinical or pharmacist standards.

CJC-1295 synonyms tracked on this site

CJC-1295 appears in the literature under several names that are not always interchangeable:

• DAC:GRF (Drug Affinity Complex Growth Releasing Factor) — the formal designation from ConjuChem
• Modified GRF 1-29 or Mod GRF 1-29 — technically refers to the variant without the DAC albumin-conjugating group; half-life approximately 30 minutes versus 5.8–8.1 days for CJC-1295 with DAC
• CJC-1295 with DAC — the albumin-conjugated variant with extended half-life
• CJC-1295 without DAC — the non-conjugated variant; pharmacologically distinct
• hGRF(1-29) analog — the generic chemical description

This site covers CJC-1295 with DAC (the form studied in the Teichman et al. 2006 human trials) as its primary subject and notes Modified GRF 1-29 for pharmacokinetic comparison.